

CLAIM AMENDMENTS

Please cancel claims 1, and 6-9 without prejudice.

1. (Canceled)

2. (Currently Amended) A method for treating or preventing acute or chronic asthma, by administering an effective amount of an FK506 derivatives-derivative and an effective amount of a β 2-agonist, ~~simultaneously, separately or sequentially~~, to a human being or an animal.

3. (Currently Amended) A composition comprising an FK506 derivatives-derivative and a β 2-agonist as a combined preparation ~~for treating or preventing acute or chronic asthma~~.

4. (Currently Amended) The ~~use method~~ of claim [[1]] 2, ~~in which~~ wherein the FK506 ~~derivatives-derivative~~ is tacrolimus or its hydrate.

5. (Currently Amended) The ~~use method~~ of claim [[1]] 2, ~~in which~~ wherein the β 2-agonist is salmeterol or formoterol.

Claims 6-9. (Canceled)

Please add the following claims.

10. (New) The method of claim 2, comprising simultaneously administering the FK506 derivative and the β 2-agonist to the human being or the animal.

11. (New) The method of claim 2, comprising separately administering the FK506 derivative and the β 2-agonist to the human being or the animal.

12. (New) The method of claim 2, comprising sequentially administering the FK506 derivative and the β 2-agonist to the human being or the animal.

13. (New) The composition of claim 3, wherein the FK506 derivative is tacrolimus or its hydrate.

14. (New) The composition of claim 3, wherein the β 2-agonist is salmeterol or formoterol.

In re Appln. of HIRAYAMA et al.
Application No. Unassigned

15. (New) The composition of claim 13, wherein the β 2-agonist is salmeterol or formoterol.

16. (New) The method of claim 4, wherein the β 2-agonist is salmeterol or formoterol.